A B S T R A C T The designing of parathyroid hormone (PTH)-renal dose-response studies in human beings is complicated by the possibility of rapid homologous receptor down-regulation, a phenomenon that is clearly shown to occur in vitro. Large amounts of PTH given to human subjects as serial injections or prolonged infusions cause decreased urinary 3',5'-cyclic adenosine monophosphate (cAMP) responses to subsequent PTH doses, but it is uncertain whether lower doses given over shorter periods similarly cause renal tachyphylaxis to PTH action. Thus, in seven water-loaded adults, we infused in ascending order 10, 30, 75, 150, and 300 U of synthetic bovine PTH fragment (bPTH 1-34) per 70 kg body wt over 15 min on widely separated days ("separate day administration"). On another day, each subject received all five 15-min doses in ascending order at 75-min intervals ("single day administration"). Urine collection intervals were control, 0-30 min (including the PTH infusion), and 30-60 min. Peak nephrogenous cAMP (NcAMP, nmol/100 ml glomerular filtrate) response was linearly related to the dose of PTH (separate day study, r = 0.94, P < 0.001; single day study, r = 0.88, P < 0.001). However, the slope of NcAMP responses plotted against PTH dose for the single day study was only 36% of that derived from separate day administration of the same PTH doses (P < 0.001). After only 40 U (10 + 30) of bPTH 1-34/70 kg, the NcAMP response to 75 U was reduced 44%, and the effect of 300 U/70 kg, when given as the last of the sequential single day infusions, was 64% less than the response to 300 U of bPTH 1-34 given alone (P < 0.001). The phosphaturic response (fractional excretion of phosphorus, FEP [percent]) was also linearly related to bPTH 1-34 dose, but combined administration of the PTH infusions on one day increased FEP at each dose identically with the effects of separate day administration. A transient, dose-related, early hypercalciuric response to bPTH 1-34 also occurred, and was of equal magnitude in both protocols. These studies demonstrate that significant blunting of the NcAMP response to bPTH 1-34 occurs rapidly and follows brief exposure to relatively low doses of hormone. In contrast, there is no effect of recent PTH administration on the phosphaturic and early hypercalciuric actions of bPTH 1-34. This seeming dissociation of PTH effects makes unclear the physiologic importance of PTH-induced cAMP tachyphylaxis in the regulation of final PTH actions. In any case, studies of NcAMP responses in which the occurrence of tachyphylaxis would be undesirable should be designed to avoid prolonged or closely spaced administrations of the hormone. INTRODUCTION The acute administration of exogenous parathyroid hormone (PTH)' causes increased urinary excretion of
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In normal human volunteers, Tomlinson et al. found that the infusion of 1,000 U of purified intact bovine PTH (bPTH 1-84) over 2 h caused an initial increase in plasma and urinary cAMP, which was followed by a progressive decline in their levels during the second hour of the infusion (9) . They also noted marked blunting of the plasma and urinary cAMP responses to a 200-U dose of bPTH 1-84 given immediately after the 1,000-U infusion (9) , as well as a progressive decrease in the responses to serial, 200 U, hourly doses (11 Infusion protocols. Each subject completed two separate infusion protocols, designated "separate day" and "single day" administration, which are depicted in Fig. 1 . All studies were completed within a single 8-wk interval (fall, 1981) . The timing of urine collection, blood sampling, and bPTH 1-34 infusion was as indicated. 90 min before the first infusion, we placed a catheter in each forearm, one for bPTH 1-34 infusion and one for blood sampling. The volunteers voided 60 min before the infusion that began each day's study, and remained seated in a lounge chair except to urinate. Each subject underwent the separate day administration protocol first; on 5 separate days, they received in sequence 10, 30, 75, 150, and 300 U of bPTH 1-34/70 kg. Although Tomlinson et al. showed that the urinary cAMP response to a 200-U bolus of bPTH 1-84 after an infusion of 1,000 U bPTH over 2 h is fully recovered within 24 h (9), we wanted to minimize the possibility of dose-dose interactions. Therefore, in our studies, the doses were given in ascending order; each dose in the separate day protocol was administered no less than 3 d after the preceding one, and at least 5 d were allowed to elapse after the 300 U/70 kg separate day infusion before the single day infusions were administered. In both protocols, the PTH infusions were performed during the first 15 min of a 30-min urine collection period, which was followed by another 30-min collection interval. In the single day protocol, the subsequent 15-min period served as a base line for the next infusion. Immediately before the first exposure to the hormone, hypersensitivity to this preparation was excluded by the instillation of two drops of a solution containing 3 U/ml of bPTH 1-34 in 0.9% NaCl into the lower conjunctival sac of one eye. There were no adverse effects of any of the studies.
Collection and preparation of samples. were prepared using the method of Feinglos et al. (18) with a minor modification. The relative insolubility of theophylline in water required excessive heating of the solution, which resulted in uncertain volume loss and precipitation of theophylline in the transferring pipette tips. Therefore, 3.6 g of theophylline and 6.7 ml of Na heparin (10,000 U/ ml) were dissolved in 293 ml of distilled water. 300 ,I of this solution was then pipetted into each tube and lyophilized to dryness. This more dilute solution was found to dissolve the theophylline at a much lower temperature and to allow transfer without precipitation. Plasma specimens were prepared for cAMP analysis using a modification of the method of Wray et al. (19, 20) . 500 ,d of each plasma sample was added suddenly to 750 ul of preheated 0.05 M Na acetate assay buffer at pH 4.9 and was incubated at 90°C for 10 min. The tubes were then centrifuged at 3,000 rpm for 15 min and the cAMP-containing supernatant (which was now at the assay buffer pH of 6.2) was removed and frozen at -20°C until analyzed.
Analyses. All samples from a given infusion were analyzed in the same assay. Serum and urinary creatinine were determined using standard autoanalyzer methods. Serum and urinary calcium were measured by atomic absorption spectrophotometry (model 2380, Perkin-Elmer Corp., Norwalk, CT). Plasma and urinary phosphorus were determined in duplicate by a colorimetric procedure (21) Urinary and plasma cAMP were determined in triplicate by radioimmunoassay using a rabbit antiserum at a final dilution of 1:400,000 (23) . The intraassay coefficient of variation was 9.9% (21 assays). NcAMP excretion was expressed as a function of glomerular filtration rate (nmol/100 ml glomerular filtrate) as described by Broadus et al. (24) . To assure that any apparent desensitization of the NcAMP response was not caused by induction of endogenous antibodies to bPTH 1-34, we assayed paired specimens from each subject for binding of 1251-bPTH 1-34 in the absence of added antiserum (25) . Samples were taken prior to the first exposure to the hormone and compared with samples taken on the morning of the last study. The mean percent binding was 7.6±0.1 (mean±SE) for the base-line specimens and 7.7±0.2 for the postexposure specimens (NS). These values were also not significantly different from nonspecific binding in other control plasmas.
Statistical analyses. The results are tabulated and depicted as mean±SE. Data were analyzed by calculation of linear regressions of responses vs. dose or log dose, and pair comparisons were made by t test, accepting significant differences at the 99% level.
RESULTS
NcAMP. For each dose in both the separate day and single day protocols, the NcAMP response was prompt and brief (Table I) P < 0.001 for both) (Fig. 2) . However, the peak values obtained from the larger doses in the single day study were significantly less than the values obtained when the same doses were given on separate days. The mean slope of the individual regressions of NcAMP on bPTH 1-34 doses for separate day administration (0.83±0.08) was nearly three times the slope of response for doses given on 1 d (0.30±0.03, P < 0.001). After a cumulative dose of only 40 U (10 + 30 U) of bPTH 1-34/ kg, the NcAMP response to 75 U/70 kg for the single day study was reduced 44% from the effect of the same dose when given alone, and the response to 300 U/70 kg given as the last of the sequential infusions was reduced 64% (P < 0.001) (Fig. 2) .
Serum calcium and plasma phosphorus. There was no significant change in serum calcium or plasma phosphorus during any of the separate day studies. During the 7¼/4-h single day protocol, serum calcium increased slightly but progressively: basal, 9.1+0.1 mg/dl; last sample, 9.4±0.1 mg/dl (P < 0.01). During this same period, plasma inorganic phosphorus concentrations decreased slightly but not significantly: basal, 3 from the start of bPTH 1-34 infusions plotted as a function of dose (U/70 kg, note log scale). -* -, doses given on separate days; ---0 ---, doses given sequentially on a single day. There are no significant differences between the early hypercalciuric responses in the two protocols; for both regressions, P < 0.001 affinity of the remaining, unoccupied receptor sites and an acute decrease in target cell sensitivity to the hormone (26) . Another possible mechanism for hormone-induced tachyphylaxis is prolonged occupancy of the receptor site by undissociated ligand, which results in a functional receptor loss (27) . In a canine renal system, such receptor loss may be reversed by addition of guanosine triphosphate (GTP) (28) . The phenomenon of homologous desensitization induced by exogenous PTH has received relatively little attention, and the mechanism(s) of this effect are uncertain. Most investigations of this subject have emphasized the cAMP response to PTH administration rather than effects on phosphate or calcium transport. Chao and Forte (3) noted a time-and dose-dependent, PTH-mediated homologous tachyphylaxis in cultured rat kidney cells, despite the presence of normal cAMP responsiveness to cholera toxin. They interpreted this as indicating that the catalytic and coupling units of the adenylate cyclase enzyme system were functioning normally, and then suggested that the locus for downregulation was at the receptor sites. Nichols and colleagues (2) had previously found that the infusion of very large doses of PTH (175 U/kg) for 8 h in rats caused a diminution both in the cAMP response of renal cortical slices to PTH and in the PTH-dependent adenylate cyclase activity of renal cortical cell membranes. A concurrent decrease in responsiveness of the enzyme to calcitonin and fluoride, but not to vasopressin, was noted in this study; this suggests that acute infusion of PTH inhibited the catalytic activity of adenyl cyclase as well as receptor-mediated activation of the enzyme by subsequent PTH challenge. Tamayo et al. (28) examined the mechanism of PTH-induced homologous desensitization in purified basolateral cortical membranes from isolated perfused canine kidneys. They found that bPTH 1-34 induced a decrease in PTH binding and in PTH-stimulated adenylate cyclase activity that could be normalized by preincubation of the membranes with GTP (which dissociates bound PTH). This suggests that tachyphylaxis was caused by persistent receptor occupancy in their in vitro model (28) .
The characteristics of PTH receptors and their functional relationship to adenyl cyclase are currently under active investigation (16, 29) . Two earlier studies in parathyroidectomized rats, which were published before the concept of homologous down-regulation appeared, presented data which suggest that tachyphylaxis occurs in phosphaturic (1, 4) and urinary cAMP (1) responses to prolonged or repetitive exogenous PTH stimulation. However, in the intact rat, even large doses of PTH given as prolonged infusions or as serial bolus injections failed to elicit refractoriness in vivo, despite the concurrent in vitro evidence of this phenomenon (2) . Studies in chicks (29) and rats (30) that were made secondarily hyperparathyroid by dietary deficiency of vitamin D or calcium have shown evidence of tachyphylaxis both in vivo and in vitro; however, the possible influence of concomitant hypocalcemia on these results was not evaluated. The applicability of these findings to human studies is uncertain because there are significant interspecies differences in the effect of PTH on cAMP production and excretion (13, 20, 31) as well as intraspecies variability in the responses to different PTH preparations (13) .
Most studies of the plasma or urinary cAMP responses to PTH administration in humans (5-10, 32, 33) have been performed in patients with primary or secondary hyperparathyroidism (HPT), which is characterized by states of chronic endogenous PTH excess.
The majority of these reports (5, 6, 9, 10, (31) (32) (33) Resistance to PTH has been provoked in rats by hypercalcemia (36) , hypermagnesemia (37) , and hypokalemia (38) , and in both rats and chicks by hypocalcemia associated with either vitamin D deficiency or a calcium-deficient diet (27, 39) . Humans with chronic renal failure (5, 9), vitamin D deficiency (32) , and some patients with primary hyperparathyroidism (6) (7) (8) (9) are also refractory to stimulation by exogenous PTH. However, our patients maintained normal blood levels of creatinine, potassium, magnesium, and calcium throughout their study periods and had normal endogenous PTH levels on the morning of the single day protocol. In addition, there was no evidence for the induction of endogenous antibodies to bPTH 1-34. The decrease of urinary cAMP responses seen in our subjects with closely spaced, small doses of PTH is consistent with the general mechanism of homologous down-regulation of peptide hormone receptors, which has been elucidated for other hormones (12 
